我武生物(300357) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥311,276,362.24, representing a year-over-year increase of 14.39%[6] - Net profit attributable to shareholders was ¥146,134,890.04, up 14.82% compared to the same period last year[6] - The net profit excluding non-recurring gains and losses was ¥139,042,241.87, reflecting a 10.71% increase year-over-year[6] - Total operating revenue for the period reached CNY 700,180,586.99, an increase of 12.97% compared to CNY 619,721,426.61 in the previous period[25] - Operating profit amounted to CNY 376,374,455.50, up from CNY 318,961,574.10, reflecting a growth of 17.94%[28] - Net profit attributable to shareholders of the parent company was CNY 327,216,170.63, compared to CNY 274,592,849.47, representing a year-on-year increase of 19.09%[30] - The total comprehensive income for the period was CNY 318,947,061.08, compared to CNY 266,291,359.95, reflecting a growth of 19.77%[30] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥250,043,126.59, showing a 3.30% increase[6] - Operating cash flow for the period was CNY 250,043,126.59, an increase from CNY 242,046,010.16 in the previous period, reflecting a growth of approximately 3.3%[32] - Cash inflow from operating activities totaled CNY 717,199,650.55, compared to CNY 597,623,360.81 in the prior period, indicating an increase of about 20%[32] - Cash outflow from operating activities was CNY 467,156,523.96, up from CNY 355,577,350.65, representing a rise of approximately 31.3%[32] - Net cash flow from investment activities was CNY 30,898,065.63, a significant improvement from a net outflow of CNY 156,597,122.56 in the previous period[35] - Cash inflow from investment activities amounted to CNY 585,555,974.38, slightly up from CNY 578,541,929.36 year-over-year[35] - Cash outflow from investment activities decreased to CNY 554,657,908.75 from CNY 735,139,051.92, showing a reduction of about 24.5%[35] - Net cash flow from financing activities was CNY -108,292,366.40, worsening from CNY -89,862,925.67 in the previous period[35] - The ending cash and cash equivalents balance was CNY 452,384,667.95, up from CNY 216,616,892.70, indicating a significant increase of approximately 108.8%[35] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,146,643,321.82, an increase of 11.11% from the end of the previous year[6] - The company's equity attributable to shareholders increased to ¥1,958,073,388.87, up 12.79% from the previous year[6] - The total assets of the company reached RMB 2.15 billion, compared to RMB 1.93 billion at the beginning of the year, reflecting an increase of about 11.2%[20] - The company's total current liabilities decreased to RMB 98.38 million from RMB 107.99 million, a reduction of approximately 8.5%[20] - The non-current assets totaled RMB 696.27 million, up from RMB 590.45 million, marking an increase of about 18%[20] - The company's total liabilities stood at CNY 136,332,083.79, slightly up from CNY 135,356,468.28, reflecting a marginal increase of 0.72%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,309[15] - The largest shareholder, Zhejiang Wawu Management Consulting Co., Ltd., holds 38.86% of shares, totaling 203,454,131 shares[15] - The company has no preferred shareholders as of the reporting period[15] Other Income and Expenses - Other income for the year-to-date period increased by ¥18,926,837.07, a growth of 171.22%, mainly from government subsidies[12] - Other income for the period was CNY 29,981,000.25, significantly higher than CNY 11,054,163.18 from the previous period, representing an increase of 171.56%[25] - Research and development expenses increased to CNY 76,318,393.79, up from CNY 60,905,616.89, marking a rise of 25.16%[25] - Employee compensation payments rose to CNY 209,137,185.70 from CNY 170,589,965.13, reflecting an increase of approximately 22.5%[32] Inventory and Accounts Receivable - Accounts receivable increased by ¥72,878,728.29, a rise of 46.68%, primarily due to increased revenue[11] - Accounts receivable rose to RMB 228.99 million, up from RMB 156.11 million, indicating a year-on-year increase of approximately 46.3%[18] - The company reported a significant increase in inventory, which decreased to RMB 47.29 million from RMB 53.75 million, a decline of approximately 12.1%[18] Product Development and Market Strategy - The company has not disclosed any new product developments or market expansion strategies in the current report[15]